Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 10/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14941563 | 0.81 | NR3C1 (0.34) | — | |
| SCHEMBL20486517 | 0.81 | NOS3 (0.35) | — | |
| SCHEMBL1600320 | 0.79 | IDO1 (0.36) | IDO1SLC6A4HTR2A | |
| SCHEMBL30108669 | 0.78 | IDO1 (0.43) | IDO1HTR1ASLC6A4HTR2AHTR2C | |
| SCHEMBL3408682 | 0.77 | IDO1 (0.46) | IDO1TAAR1 | |
| SCHEMBL500774 | 0.75 | IDO1 (0.41) | IDO1HTR1ASLC6A4HTR2AHTR2C | |
| SCHEMBL3151659 | 0.75 | — | — | |
| SCHEMBL791872 | 0.74 | IDO1 (0.46) | IDO1HTR1ASLC6A4HTR2AHTR2C | |
| SCHEMBL30945993 | 0.74 | IDO1 (0.46) | IDO1HTR1ASLC6A4HTR2AHTR2C | |
| SCHEMBL18393601 | 0.74 | CA2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1434624-B1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PROD INC (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050032847-A1 | 2-amino-6(2,4,5-substitued-phenyl)-pyridines | PFIZER INC. | 2005-02-10 | — | — | US | disclosed |
| US-6803470-B2 | NITRIC OXIDE SYNTHASE INHIBITORS. | PFIZER INC | 2004-10-12 | — | — | US | disclosed |
| EP-1434624-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | Pfizer Products Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| US-20040077853-A1 | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2004-04-22 | — | — | US | disclosed |
| US-20030087891-A1 | 2-Amino-6-(2,4,5-substituted-phenyl)-pyridines | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| WO-2003030993-A1 | 2-AMINO-6-(2,4,5-SUBSTITUTED-PHENYL)-PYRIDINES FOR USE AS NITRIC OXIDE SYNTHASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087891-A1 | 2-Amino-6-(2,4,5-substituted-phenyl)-pyridines | PNMT, HTR6, HTR2C | IDO1 169/4885HTR1A 26/4885SLC6A4 30/4885 |
| US-20040077853-A1 | 2-amino-6-(2,4,5-substituted-phenyl)-pyridines | NOS3, NOS1, NOS2 | IDO1 221/4885HTR1A 556/4885SLC6A4 1261/4885 |
| US-20050032847-A1 | 2-amino-6(2,4,5-substitued-phenyl)-pyridines | PNMT, HTR6, HTR2C | IDO1 172/4885HTR1A 21/4885SLC6A4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.